MedTrace Logo

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

NCT03785067 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-04-01

No results posted yet for this study

Summary

A Sub-Study of an investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to determine the effect of more intensive long-term blood pressure control, provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, for slowing memory decline as measured by Cambridge Neuropsychological Test Automated Battery (CANTAB), in patients with a history of acute stroke due to intracerebral haemorrhage (ICH).

Conditions

Interventions

DRUG

telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg

1 capsule taken orally once daily for 36 months

DRUG

Placebo oral capsule

1 capsule taken orally once daily for 36 months

Sponsors & Collaborators

  • University of Sydney

    collaborator OTHER

  • The George Institute

    lead OTHER

Principal Investigators

  • Prof Craig Anderson · The George Institute

  • Prof Sharon Naismith · University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2021-02-03
Completion
2021-02-03

Countries

  • Australia
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03785067 on ClinicalTrials.gov